Contact Us
中文
日本語
한국어
Careers
Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts
About Us
In Vivo Animal & Cell Models
Assets Licensing
Antibody Discovery
RenMice™ Platforms
Contact Us Online!
Menu
About Us
Our Sites
Executive Leadership
Gene Editing
By Technologies
CRISPR/EGE™-based Gene Editing
ESC-Based Gene Editing
Transgenic Technology
Other Services
By Strategies
Conventional Knockout/Knockin
Conditional Knockout/Knockin
Point Mutation Knockin
Rosa26 Locus Knockin
Tag and Reporter Genes
Tol2 Transgenic
In Vivo Models
Animal Models
Humanized Immune-Checkpoint Mice
Humanized Cytokine Mice
Humanized GPCR Mice
Immunodeficient (B-NDG) Mice
Cre Mouse/Rat Models
Other Genetically Modified Mouse/Rat Models
Other Humanized Models
Cell lines
Humanized Tumor Cell Lines
Other Cancer Cell Lines
Efficacy & Toxicity Studies
NASH Mouse Models
In Vivo Pharmacology Services
Inflammatory Disease Modeling
EAE Model
Asthma Model
Psoriasis Model
Atopic Dermatitis Model
Rheumatoid Arthritis Model
Inflammatory Bowel Disease Model
Antibody Screening Using Syngeneic Tumor Models
CAR-T Efficacy Evaluation
Anti-Tumor Efficacy in CDX & Humanized Models
PK Assays and PD Assays
Efficacy & Toxicity Case Studies
Metabolic Disease Modeling
Type II diabetes model
HFMCD induced NASH Model
Western Diet induced NASH Model
Carbon Tetrachloride (CCl4)-induced Model
RenMice™ Platforms
bsAb Discovery Platform
Bispecific ADC Platform
TCR-Mimic Antibody Platform
Anti-GPCR Antibody Technology Platform
Antibody Assets
Antibody Hits Library
Agonistic anti-CD40 IgG2 antibody YH003
Anti-CTLA-4 IgG1 monoclonal antibody YH001
Anti-OX40 IgG1 antibody YH002
Agonistic anti-4-1BB IgG1 antibody YH004
Anti-Claudin 18.2 antibody YH005
Anti-PD-1/CD40 bispecific antibody YH008
CTLA-4/OX40 bispecific antibody YH006
Anti-RSV antibody YH009
PD-L1/IL-12 bispecific antibody YH010
Bifunctional molecule YH011
Bispecific ADCs YH012, YH013
News & Resources
Brochures
Posters
Publications
Webinars
Posts
FAQs
Investors
Menu
Webinar Slides: In Vivo vs. In Vitro Therapeutic Antibody Discovery
Home
Brochures
Webinar Slides: In Vivo vs. In Vitro Therapeutic Antibody Discovery
Webinar Slides: In Vivo vs. In Vitro Therapeutic Antibody Discovery
Download slides here
Share:
Please fill out the form below to request a download of this brochure
First Name
*
Last Name
*
Work Email
*
Company/ Institution
*
Country
*
- -
Aruba
Afghanistan
Angola
Anguilla
Åland Islands
Albania
Andorra
United Arab Emirates
Argentina
Armenia
American Samoa
Antarctica
French Southern Territories
Antigua and Barbuda
Australia
Austria
Azerbaijan
Burundi
Belgium
Benin
Bonaire, Sint Eustatius and Saba
Burkina Faso
Bangladesh
Bulgaria
Bahrain
Bahamas
Bosnia and Herzegovina
Saint Barthélemy
Belarus
Belize
Bermuda
Bolivia, Plurinational State of
Brazil
Barbados
Brunei Darussalam
Bhutan
Bouvet Island
Botswana
Central African Republic
Canada
Cocos (Keeling) Islands
Switzerland
Chile
China
Côte d'Ivoire
Cameroon
Congo, the Democratic Republic of the
Congo
Cook Islands
Colombia
Comoros
Cape Verde
Costa Rica
Cuba
Curaçao
Christmas Island
Cayman Islands
Cyprus
Czech Republic
Germany
Djibouti
Dominica
Denmark
Dominican Republic
Algeria
Ecuador
Egypt
Eritrea
Western Sahara
Spain
Estonia
Ethiopia
Finland
Fiji
Falkland Islands (Malvinas)
France
Faroe Islands
Micronesia, Federated States of
Gabon
United Kingdom
Georgia
Guernsey
Ghana
Gibraltar
Guinea
Guadeloupe
Gambia
Guinea-Bissau
Equatorial Guinea
Greece
Grenada
Greenland
Guatemala
French Guiana
Guam
Guyana
Hong Kong
Heard Island and McDonald Islands
Honduras
Croatia
Haiti
Hungary
Indonesia
Isle of Man
India
British Indian Ocean Territory
Ireland
Iran, Islamic Republic of
Iraq
Iceland
Israel
Italy
Jamaica
Jersey
Jordan
Japan
Kazakhstan
Kenya
Kyrgyzstan
Cambodia
Kiribati
Saint Kitts and Nevis
Korea, Republic of
Kuwait
Lao People's Democratic Republic
Lebanon
Liberia
Libya
Saint Lucia
Liechtenstein
Sri Lanka
Lesotho
Lithuania
Luxembourg
Latvia
Macao
Saint Martin (French part)
Morocco
Monaco
Moldova, Republic of
Madagascar
Maldives
Mexico
Marshall Islands
Macedonia, the former Yugoslav Republic of
Mali
Malta
Myanmar
Montenegro
Mongolia
Northern Mariana Islands
Mozambique
Mauritania
Montserrat
Martinique
Mauritius
Malawi
Malaysia
Mayotte
Namibia
New Caledonia
Niger
Norfolk Island
Nigeria
Nicaragua
Niue
Netherlands
Norway
Nepal
Nauru
New Zealand
Oman
Pakistan
Panama
Pitcairn
Peru
Philippines
Palau
Papua New Guinea
Poland
Puerto Rico
Korea, Democratic People's Republic of
Portugal
Paraguay
Palestine, State of
French Polynesia
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saudi Arabia
Sudan
Senegal
Singapore
South Georgia and the South Sandwich Islands
Saint Helena, Ascension and Tristan da Cunha
Svalbard and Jan Mayen
Solomon Islands
Sierra Leone
El Salvador
San Marino
Somalia
Saint Pierre and Miquelon
Serbia
South Sudan
Sao Tome and Principe
Suriname
Slovakia
Slovenia
Sweden
Swaziland
Sint Maarten (Dutch part)
Seychelles
Syrian Arab Republic
Turks and Caicos Islands
Chad
Togo
Thailand
Tajikistan
Tokelau
Turkmenistan
Timor-Leste
Tonga
Trinidad and Tobago
Tunisia
Turkey
Tuvalu
Taiwan, Province of China
Tanzania, United Republic of
Uganda
Ukraine
United States Minor Outlying Islands
Uruguay
United States
Uzbekistan
Holy See (Vatican City State)
Saint Vincent and the Grenadines
Venezuela, Bolivarian Republic of
Virgin Islands, British
Virgin Islands, U.S.
Viet Nam
Vanuatu
Wallis and Futuna
Samoa
Yemen
South Africa
Zambia
Zimbabwe
State/ Province
*
How did you hear about us?
*
Event/tradeshow
Referral/Word of mouth
Existing client
Social Media
Online Search
Promotional Email/Email Marketing
Other
Question/Comment:
Is fire hot or cold?
We use cookies to personalize content, analyze traffic, and ensure that we give you the best experience on our website.
Click To Continue
